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OBJECTIVE—Several whole-genome association studies have
reported identiﬁcation of type 2 diabetes susceptibility genes in
various European-derived study populations. Little investigation
of these loci has been reported in other ethnic groups, speciﬁ-
cally African Americans. Striking differences exist between these
populations, suggesting they may not share identical genetic risk
factors. Our objective was to examine the inﬂuence of type 2
diabetes genes identiﬁed in whole-genome association studies in
a large African American case-control population.
RESEARCH DESIGN AND METHODS—Single nucleotide
polymorphisms (SNPs) in 12 loci (e.g., TCF7L2, IDE/KIF11/
HHEX, SLC30A8, CDKAL1, PKN2, IGF2BP2, FLJ39370, and
EXT2/ALX4) associated with type 2 diabetes in European-
derived populations were genotyped in 993 African American
type 2 diabetic and 1,054 African American control subjects.
Additionally, 68 ancestry-informative markers were genotyped to
account for the impact of admixture on association results.
RESULTS—Little evidence of association was observed be-
tween SNPs, with the exception of those in TCF7L2, and type 2
diabetes in African Americans. One TCF7L2 SNP (rs7903146)
showed compelling evidence of association with type 2 diabetes
(admixture-adjusted additive P [Pa]  1.59  10
6). Only the
intragenic SNP on 11p12 (rs9300039, dominant P [Pd]  0.029)
was also associated with type 2 diabetes after admixture adjust-
ments. Interestingly, four of the SNPs are monomorphic in the
Yoruba population of the HAPMAP project, with only the risk
allele from the populations of European descent present.
CONCLUSIONS—Results suggest that these variants do not
signiﬁcantly contribute to interindividual susceptibility to type 2
diabetes in African Americans. Consequently, genes contributing
to type 2 diabetes in African Americans may, in part, be different
from those in European-derived study populations. High fre-
quency of risk alleles in several of these genes may, however,
contribute to the increased prevalence of type 2 diabetes in
African Americans. Diabetes 57:2220–2225, 2008
R
ecently, several whole-genome association
(WGA) studies have reported evidence for the
existence of multiple type 2 diabetes suscepti-
bility genes. These results were primarily ob-
served in different European-derived study populations.
Included in these loci are polymorphisms in TCF7L2
(1–5), HHEX (1–6), SLC30A8 (1–4,6), CDKAL1 (2–6),
IGF2BP2 (3–6), FTO (4–7), PKN2 (3,4), FLJ39370 (3),
EXT2/ALX4 (1), and LOC387761 (1). Despite the compel-
ling evidence of association of many of these genes in
European-derived study populations, little or no investiga-
tion of association has been reported for African Ameri-
cans.
Differences between European-derived and African Amer-
ican populations (e.g., haplotype block structure and allele
frequency discrepancies) suggest that the genetic risk
factors of each may not be identical. Previously, we have
reported that common genetic variants in TCF7L2 and
HNF4A contribute to type 2 diabetes in African Ameri-
cans, whereas polymorphisms in CAPN10, TCF1, and
PPARG have little or no evidence of association (8). Lack
of association with other type 2 diabetes susceptibility loci
in African Americans has also been observed (9). In
addition, differences in allele frequencies of risk polymor-
phisms between ethnicities have been shown (e.g., Chan-
dalia et al. [10]). These substantial discrepancies could
contribute to the differences in overall prevalence of type
2 diabetes within these ethnic groups. Consequently, we
examined the inﬂuence of single nucleotide polymor-
phisms (SNPs) recently identiﬁed in WGA studies on type
2 diabetes susceptibility in a large African American
case-control population.
RESEARCH DESIGN AND METHODS
Recruitment of patients and control subjects has previously been described
(11). Brieﬂy, 993 unrelated African American patients with type 2 diabetes
born in Virginia, Tennessee, North Carolina, South Carolina, or Georgia were
recruited from dialysis clinics. Type 2 diabetes was diagnosed if patients
reported an initial diagnosis of diabetes after 35 years of age, received dietary
therapy or hypoglycemic agents in the absence of insulin alone for at least 1
year after initial diagnosis, and were currently receiving diabetes medications.
Case subjects had severe diabetes accompanied by nephropathy, and type 2
diabetes was diagnosed 5 years before the start of renal replacement
therapy, with background or greater diabetic retinopathy and/or a score of
3 proteinuria on dipstick urinalysis. Nondiabetic control subjects were
recruited from the same geographic region: 1,054 were African American and
36 European descent–derived without prior diagnosis of type 2 diabetes or
renal disease. DNA extraction was performed using the PureGene system
(Gentra Systems, Minneapolis, MN). DNA was obtained from 44 Yoruba
Nigerians from the National Institute of General Medical Sciences Human
Variation Collection (Coriell Cell Repositories, Camden, NJ). This study was
approved by the institutional review board of Wake Forest University School
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Candidate gene genotyping. SNPs PKN2 rs6698181; IGF2BP2 rs4402960;
FLJ39370 rs17044137; CDKAL1 rs10946398 and rs7754840; SLC30A8
rs13266634; CDKN2A/CDKN2B rs564398 and rs10811661; HHEX/IDE/KIF11
rs1111875, rs5015480, and rs7923837; EXT2/ALX4 rs3740878, rs11037909, and
rs1113132; FTO rs8050136; LOC387761 rs7480010; intragenic rs9300039; and
TCF7L2 rs7903146 were genotyped using iPlex technology (Sequenom, San
Diego, CA) (12). Primer sequences are available on request. SNP genotyping
success rates were 98.6% in case and 98.4% in control subjects. Concor-
dance between blind duplicate samples included in the genotyping was
99.5%.
Admixture analyses genotyping. Sixty-eight biallelic ancestry-informative
markers were genotyped using iPlex technology (Sequenom, San Diego, CA)
in 993 African American case, 1,054 African American control, 44 Yoruba
Nigerian, and 36 European-American subjects. Both the Yoruba Nigerian and
European-American individuals were utilized only for admixture analyses.
Primer sequences are available on request. Genotyping success rates for
ancestry-informative markers were 96.9% in African American case and
95.2% in African American control subjects.
Statistical analyses. Hardy-Weinberg equilibrium (HWE) values were deter-
mined by calculating a 
2 statistic and corresponding P value. Structures of
the haplotype blocks for the SNPs genotyped in CDKAL1, EXT2/ALX4, and
IDE/KIF11/HHEX were ascertained using Haploview 3.2 (13) using the
criteria outlined by Gabriel et al. (14).
Measures of linkage disequilibrium and association were calculated using
the program SNPGWA (15). For each tandem pair of SNPs, the linkage
disequilibrium statistics D and r
2 were computed. Multiple tests of associa-
tion including the overall 2 d.f. (genotypic), additive (Cochran-Armitage trend
test), and corresponding lack of ﬁt to additivity were calculated. Tests of
association under the dominant and recessive genetic models are also
reported. Haplotypic association was calculated using the expectation-maxi-
mization algorithm implemented in this program. Initially, tests were per-
formed using 1,000 permutations. Where association tests indicated possible
signiﬁcance (empirical P  0.10), permutations were increased to 10,000. The
quantitative trait (BMI) association analysis for FTO SNP rs8050136 was
performed using a module of SNPGWA (QSNPGWA). Association values
adjusted for age or sex were calculated using the program SNPADDMIX.
Estimates of case and control haplotype frequency were obtained using
Dandelion 1.26 (16).
To provide context for these tests of association, power analyses were
computed using QUANTO (17). Speciﬁcally, power estimates to detect the
range of reported odds ratios (ORs) from the European-derived samples were
computed assuming a type 2 diabetic population prevalence of 0.15 (consis-
tent with African American populations) and polymorphism-speciﬁc type 1
error rates of 	0.05 and 	0.10. Power was calculated based on the risk
allele frequency observed in our African American sample.
Individual ancestral proportions were calculated using an expectation-
maximization algorithm (FRAPPE) (18) under a two-population model. Esti-
mates of ancestral allele frequencies were obtained from the genotyped
African American and European-derived samples. Logistic regression tests of
additive, dominant, and recessive genetic models included adjustments for
individual estimates of African ancestry (19).
RESULTS
Eighteen SNPs in 12 type 2 diabetes loci previously
associated in European-derived populations were geno-
typed in a sample of 993 African American type 2 diabetic
case subjects enriched for diabetic nephropathy and in
1,054 African American control subjects. Characteristics
of the study population are shown in Table 1. Within this
cohort, we observed a greater percentage of female sub-
jects in the case (63%) compared with the control subjects
(55%). Control subjects were younger than case subjects
but older than the mean age at which type 2 diabetes was
diagnosed. The ages of 26% of the control subjects were
unavailable. The mean age of end-stage renal disease
diagnosis was 58.4 
 10.5 years. In the case subjects, the
estimated mean proportion of African ancestry was 0.821,
whereas in the control subjects it was 0.795.
All SNPs were consistent with HWE proportions in the
entire population (supplementary Table 1 [available in an
online appendix at http://dx.doi.org/10.2337/db07-1319]).
rs9300039, which is located in an intragenic region of
chromosome 11p12, was inconsistent with HWE in the
case population (P  0.028) because of an excess of
homozygotes. All SNPs examined were in HWE in the
control population.
High levels of linkage disequilibrium were observed
between the two CDKAL1 SNPs rs10946398 and rs7754840
(D1.000; r
2  0.996). The three SNPs within the
IDE/KIF11/HHEX region were in high-to-moderate link-
age disequilibrium with pairwise D values of 0.679 (r
2 
0.244) between rs1111875 and rs5015480, 0.945 (r
2 
0.140) between rs5015480 and rs7923837, and 0.894 (r
2 
0.236) between rs1111875 and rs7923837. Likewise, high
linkage disequilibrium was also observed within the three
SNPs in the EXT2/ALX4 region, with pairwise D values of
1.000 (r
2  0.569) between rs1113132 and rs11037909,
0.988 (r
2  0.601) between rs11037909 and rs3740878, and
1.000 (r
2  0.935) between rs1113132 and rs3740878.
Results of the single-SNP association analyses are
shown in Table 2. Genotype frequencies and counts for
each SNP are provided in supplementary Table 1. Evi-
dence of association with type 2 diabetes was observed
with rs10946398 (OR 1.15; additive P [Pa]  0.029) and
rs7754840 (OR 1.14; Pa  0.039), both of which are located
in intron ﬁve of CDKAL1. However, after adjusting for
admixture, neither SNP remained nominally signiﬁcant. A
signiﬁcant association with type 2 diabetes was also seen
with LOC387761 SNP rs7480010 (OR 1.33; Pa  0.002), but
this marker also did not show evidence of association after
adjusting for admixture (Pa  0.084). rs9300039, located in
an intragenic region of chromosome 11p12, was also
associated under the admixture-adjusted dominant model
(Pd  0.029) but deviated from HWE proportions in the
case population (HWE P  0.028). In addition, the minor
allele homozygote count for rs9300039 is small (21 in the
case and 9 in the control subjects, respectively [supple-
mentary Table 1]), so association values for this marker
should be interpreted with caution. The most signiﬁcant
TABLE 1
Characteristics of African American study participants
Trait
Type 2 diabetes–
ESRD case subjects Control subjects
n* Mean 
 SD n* Mean 
 SD
Female 993† — 1,054† —
Age at exam (years) 957 61.8 
 10.2 781 51.4 
 11.4
Age at type 1 diabetes diagnosis (years) 965 41.3 
 12.2 — N/A
Age at ESRD diagnosis (years) 990 58.4 
 10.5 — N/A
*Number with data available. †Sixty-three percent (622) of type 2 diabetes–ESRD case subjects and 55% (582) of control subjects were
female. ESRD, end-stage renal disease.
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TCF7L2 SNP rs7903146 (OR 1.39; Pa  1.73  10
6), and
this SNP remained statistically signiﬁcant after admixture
adjustment (Pa  1.59  10
6). All other SNPs examined
failed to show evidence of association with type 2 diabetes
in this African American cohort under an additive model
(Table 2). Tests of association under the dominant and
recessive genetic models are shown in supplementary
Table 2. We also tested whether FTO SNP rs8050136 was
associated with BMI as previously reported in European-
derived populations (4,6). We found no evidence of asso-
ciation with this polymorphism and BMI (Pa  0.480).
Association with type 2 diabetes adjusted for age or sex
was calculated for each SNP (data not shown) but did not
meaningfully change the results of this study.
It is interesting to note that 5 of the 18 SNPs had ORs in
the opposite direction, inconsistent with the previously
reported OR. In fact, the 95% CI for 7 of the 18 SNPs did
not include the previously reported OR from the European-
American samples.
With this very limited evidence of association in our
African American population, the question arises whether
adequate power was available in this sample to detect
association. This has been addressed by calculating the
power to detect association for each SNP based on the
estimated effect size from studies in European-derived
populations and the observed allele frequency of the risk
allele in the African American population. Power was
calculated for 	0.05 (nominal evidence of association)
and 	0.10 (for the ability to detect loci that are trending
toward association). The power estimates using an inter-
mediate measure of effect size (between the highest and
lowest reported in European-derived populations) under
the additive model are shown in Table 2. More extensive
power estimates are shown in supplementary Table 3,
which also provides estimates for high and low observed
effect sizes. For some SNPs, the power is quite low (e.g.,
rs7480010) but for other SNPs (rs3740878, rs11037909, and
rs8050136) power is 70% for 	0.05.
All three SNPs examined in the EXT2/ALX4 region
reside in a single linkage disequilibrium block but showed
no haplotypic association with type 2 diabetes (data not
shown). Of the three SNPs genotyped in the IDE/KIF11/
HHEX region, two (rs5015480 and rs7923837) were lo-
cated in an linkage disequilibrium block but also showed
no evidence of association. Haplotype analysis of the two
CDKAL1 SNPs (rs10946398 and rs7754840) show signiﬁ-
cant association with type 2 diabetes (global empirical P 
0.036; data not shown) but provides little information
beyond that obtained with single-SNP analysis as a result
of high measures of linkage disequilibrium (D1.000; r
2
 0.996).
DISCUSSION
We examined 18 SNPs in 12 loci identiﬁed in recent
genome-wide association studies in European-derived
populations that were associated with type 2 diabetes or
BMI (FTO) for association with type 2 diabetes in a large
African American population. There is very limited evi-
dence that any of these European-derived genome-wide
association study SNPs contribute to diabetes in African
Americans. In contrast, signiﬁcant association with type 2
diabetes was observed with the previously described
TCF7L2 SNP rs7903146. TCF7L2 has been the focus of
multiple investigations and is one of the most highly
replicated type 2 diabetes candidate genes in several
populations (1–5). Few publications have examined the
inﬂuence of TCF7L2 on type 2 diabetes risk in African
Americans. In this study, we expand on the previous
investigation from our center by Sale et al. (8), which
described compelling evidence of association with type 2
diabetes for polymorphisms in this gene. From the results
of these studies and the convincing replication of asso-
ciation with type 2 diabetes in European-derived pop-
ulations, a more comprehensive study of TCF7L2
polymorphisms in African Americans is warranted. Par-
enthetically, this observation of strong association gives
us conﬁdence that the ascertainment and diagnoses
used to recruit these African American subjects are
accurate and the analyses of the European-derived type
2 diabetes loci presented here are valid.
TABLE 3
Minor allele frequencies for African American, YRI, and CEU populations
Reported risk allele frequency
SNP Alleles
Reported risk
allele
African American
frequency
HAPMAP
frequency (YRI)
HAPMAP
frequency (CEU)
rs6698181 C/T T 0.155 0.050 0.367
rs4402960 T/G T 0.527 0.550 0.292
rs17044137 T/A A 0.327 0.400 0.258
rs10946398 C/A C 0.598 0.667 0.308
rs7754840 C/G C 0.600 0.667 0.308
rs13266634 C/T C 0.915 0.942 0.750
rs564398 T/C T 0.939 1.000 0.625
rs10811661 T/C T 0.930 1.000 0.792
rs1111875 C/T C 0.770 0.858 0.558
rs5015480 C/T C 0.627 0.568 0.552
rs7923837 G/A G 0.923 1.000 0.625
rs9300039 C/A C 0.886 0.831 0.892
rs7480010 G/A G 0.873 1.000 0.246
rs1113132 C/G C 0.918 0.925 0.700
rs11037909 T/C T 0.860 0.842 0.700
rs3740878 A/G A 0.911 0.924 0.698
rs8050136 C/A A 0.449 0.467 0.450
rs7903146 C/T T 0.319 0.292 0.250
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signiﬁcant association with type 2 diabetes in African
Americans before admixture adjustment was observed
with the SNPs located in CDKAL1 and LOC387761.I fo n e
takes into consideration that multiple SNPs were geno-
typed, any standard multiple-comparisons correction sug-
gests that the evidence for association is very modest.
Both rs10946398 and rs7754840 have been previously
associated with type 2 diabetes in European-derived pop-
ulations (3,4,6). In addition, other publications have also
reported evidence of association in this region, making
CDKAL1 one of the most highly replicated genes identiﬁed
from recent WGA studies (2,5). Measures of linkage dis-
equilibrium between rs10946398 and rs7754840 in African
Americans (D1.000; r
2  0.996) were similar to those
reported in European Americans (6). In contrast, the
frequencies of the rs10946398 and rs7754840 risk allele (C
for both) differed substantially between African American
(0.60, 0.60), Yoruba in Ibaden, Nigeria (YRI) (0.67, 0.67),
and Utah residents with ancestry from northern and
western Europe (CEU) (0.31, 031) populations. In addi-
tion, FTO SNP rs8050136 was previously associated with
BMI (7); however, we found no evidence of association
with this trait in any genetic model.
The genotyping data have been evaluated for associa-
tion with type 2 diabetes taking into consideration the
European-African admixture of African Americans. We
have adjusted association statistics using estimates of
individual proportions of European and African ancestry
for each subject. This approach may under- or over-
estimate the true association at each locus because the
difference in allele frequencies between the ancestral
populations might vary at each marker, and, thus, the
adjustment for an individual genome may overestimate or
underestimate admixture at a speciﬁc site. Thus, it is
possible in this dataset that stronger evidence of associa-
tion might be revealed by a locus-speciﬁc analysis. Given
the magnitude of the great majority of the P values
observed here (Table 2), this inﬂuence would have to be
very substantial to adjust the P values into the range
suggesting association.
Even though all of the SNPs examined in this study
showed highly signiﬁcant association with type 2 diabetes
in European-derived populations, we found limited evi-
dence of association with these markers in African Amer-
icans. For some of these SNPs, we have limited power to
detect evidence of association given the sample sizes,
allele frequencies, and effect sizes (Table 2) (supplemen-
tary Table 3). There is, however, reasonable power to
detect association for a number of the SNPs. It is impor-
tant to note that these conventional power analyses reﬂect
the power to detect association at a single locus. If one
takes into consideration the overall study, we would have
expected to see evidence of association with four to ﬁve
loci at 	0.05.
Another caveat to this study is that we have tested only
one to three SNPs per gene that were highly associated in
European-derived populations. Ongoing extensive analy-
ses of individual genes, a pending genome-wide associa-
tion study in these samples, and genotyping in additional
samples of case and control subjects will further clarify
the role of these loci in the African American diabetic
population. The absence of association that was observed
in this study may, however, be accountable to differences
in genetic risk factors that exist between African and
European-derived populations. Moreover, multiple other
type 2 diabetes susceptibility genes reported in popula-
tions with European descent fail to show association in
African-derived samples (9).
Disparities in allele frequencies between different ethnic
groups may impair our ability to observe true associations
if they exist in African Americans. For example, the type 2
diabetes risk allele reported by recent WGA studies for
CDKN2A/CDKN2B SNPs rs10811661 and rs564398, IDE/
KIF11/HHEX SNP rs7923837, and LOC387761 SNP
rs7480010 have frequencies of 1.00, i.e., are monomorphic,
in the YRI population of the HAPMAP project (20) (Table
3). This observation presumes that Yoruba subjects are
representative of all African populations. We have com-
pared these sequences with chimpanzee and other avail-
able primate sequences, but no common pattern of
sequence variation is apparent. Presumably, the non-
African alleles for these loci are the result of European
admixture, which is not great enough to provide an
observable level of protection from type 2 diabetes. The
observation that these loci are nonpolymorphic in Africans
and that solely Africans have the risk allele suggests that
these loci may, in part, contribute to the increased overall
prevalence of type 2 diabetes in African-derived popula-
tions compared with that in European-derived popula-
tions. Thus, the appropriate conclusion from this study is
that these European type 2 diabetes susceptibility loci do
not measurably contribute to differential susceptibility in
the African American population.
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